Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Female patients aged 18-70 years.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. HR+ was defined as estrogen receptor- or progesterone receptor-positive status by immunohistochemistry.
4. HER2 status was determined by immunohistochemistry or fluorescence in situ hybridization.
5. Palbociclib treatment of metastatic breast cancer for at least one cycle.
6. Available medical history.
You may not be if
1.Incomplete medical history.
Clareo Health | Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
